Bayer

Contact Us

Publications

Publications

At Bayer, we are working in collaboration with the leading scientific, academic, and community partners to improve our understanding of cardiorenal diseases.  

 

We invite you to explore Bayer-supported publications pertaining to chronic kidney disease associated with type 2 diabetes. This library is not intended to serve as a comprehensive repository of all publications. Publications not supported by Bayer are not included. Access to the full text of publications may depend on journal access rights.

 

To help narrow down your search, choose the relevant tags and click apply. Applying multiple tags will narrow your results.

 

Last updated "June 6, 2025".

Types of Enhancements Available

audio
Audio
infographic
Graphical Abstract
PLS
Plain Language Summary
video
Video
other
Others

To help narrow down your search, select the relevant filters from the dropdowns and Click Apply

Hold down Ctrl key on keyboard to select multiple years

Total available publications: 199    

Filtered results: 199

Finerenone with empagliflozin in chronic kidney disease and type 2 diabetes

Agarwal R, et al. New England Journal of Medicine. 2025.

Agarwal, R., Green, J.B., Heerspink, H.J., et al., 05 06 2025
READ
EMAIL

The role of finerenone in the concomitant management of chronic kidney disease-type 2 diabetes and the implication for heart failure prevention and treatment

Taub PR, et al. Heart Failure Reviews. 2025;1-4.

Taub PR, Greene SJ, Fudim M, 31 05 2025
READ
EMAIL

Albuminuria as a diagnostic criterion and a therapeutic target in heart failure and other cardiovascular disease

Bozkurt B, et al. European Journal of Heart Failure. 2025.

Bozkurt B, Rossignol P, Vassalotti JA, 27 05 2025
READ
EMAIL

Finerenone effects on biomarkers: an analysis from the FIGARO-DKD trial

Berger M, et al. European Heart Journal. 2025;ehaf316.

Berger M, MacNamara A, Ferreira JP, et al., 26 05 2025
READ
EMAIL

Efficacy and safety of finerenone in Asian patients with type 2 diabetes and chronic kidney disease: A FIDELITY analysis

Wada T, et al. Kidney Diseases. Online ahead of print.

Wada T, Anker SD, Liu Z, et al., 22 05 2025
READ
EMAIL

Use of finerenone in patients with chronic kidney disease at high risk of heart failure

Hakim JP, et al. Hypertension Research. 2025;169:156297.

Hakim, J. P., Handelsman, Y., Banerjee, T., 12 05 2025
READ
EMAIL

Finerenone: Potential clinical application across the spectrum of cardiovascular disease and chronic kidney disease

Haq N, et al. Journal of Clinical Medicine. 2025;14(9):3213.

Haq N, Uppal P, Abedin T, Lala A, 06 05 2025
READ
EMAIL

Impact of finerenone on chronic kidney disease progression in Chinese patients with type 2 diabetes: a FIGARO-DKD subgroup analysis

Li P et al. Front Endocrinol. 2025;1568438.

Li P, Zheng H , Ma J, 29 04 2025
READ
EMAIL

Incident hyperkalaemia risk model in chronic kidney disease and diabetes: the FIDELITY programme

Ferreira JP et al. European Heart Journal . 2025;00:1-9.

Ferreira JP, Anker SD, Palmer BF, 22 04 2025
READ
EMAIL

The interplay between heart failure and chronic kidney disease

Lala A et al. Diabetes Obes Metab. 2025;1-15.

Lala A, Levin A, Khunti K , 21 04 2025
READ
EMAIL

Follow Us

You are encouraged to report side effects or quality complaints of products to the FDA by visiting www.fda.gov/medwatch or calling 1-800-FDA-1088. For Bayer products, you can report these directly to Bayer by clicking here.

 

This site provides access to balanced and evidence-based medical information related to our therapeutic areas of focus and is intended to serve as a medical resource for US HCPs. This may include investigational compounds or investigational new uses of FDA-approved Bayer products. The information provided is not intended to be promotional or provide medical advice. Please refer to the full Prescribing Information for approved indications, contraindications, warnings and precautions, and adverse events.

Copyright © 2025 Bayer

Bayer and the Bayer Cross are registered trademarks of Bayer.

sitemap